It is genuinely amazing that outside the fact when this IPO'd at...

It is genuinely amazing that outside the fact when this IPO'd at $1+ with the same revenues being received and relatively the same clients (the only major change was the removal of Sepsidx and Uridx products) even with FDA approval exactly 12 months ago at.17c, the current price dictates that NOTHING has happened to the company to factor any substantial growth in SP value which is absurd.

I would take it that unless a NEW product with ONGOING revenue is released from one of our service partners, OR, the manufacturing / licencing agreement for Febridx comes to light OR FFN test is done quicker than expected, OR, CLIA waiver is received sooner than expected OR full FDA approval for Viradx is obtained OR Australian distributors for Febridx get announced OR something else which hasnt been discussed comes to light, nothing appears to change in the short term.

The mind does boggle. No debt, and one could assume near double annual revenues compared to last year (10M USD services revenue, plus $10M FFN agreement, plus DOUBLE product sales from last year.

Holders from .01c could still be churning stocks for profits and retailers trading and averaging down? Zero substantial holding notices coming out, so who knows what is actually occurring on the books.